The personalised healthcare subsidiary of NantWorks, backed by Celgene, Blackberry and Allscripts, has priced its initial public offering at $14 a share.
NantHealth, the personalised healthcare technology developer that is a spinout of US-based health technology producer NantWorks and backed by several corporates, began trading on Nasdaq yesterday raising $91m.
The company priced 6.5 million shares at $14 each. The proceeds are marginally less than the $92m the company previously aimed for when it filed in May 2016.
NantHealth is working on diagnostics technology that analyses the molecular profile of a patient’s tissue so that drugs can be prescribed more efficiently.…
